Emergências e Terapia Intensiva
Perspectiva | Variante Delta aciona uma nova e perigosa fase da pandemia.
24 Jun, 2021 | 11:03hDelta variant triggers dangerous new phase in the pandemic – Science
CDC | Vacinas de mRNA parecem ter ligação com casos de miocardite e pericardite – 1.226 casos de miocardite ou pericardite foram relatados, a maioria em pessoas com menos de 30 anos de idade.
24 Jun, 2021 | 11:00hVer também: Experts: mRNA COVID-19 vaccines likely tied to heart inflammation – CIDRAP
Relacionados: Case series: 7 cases of myocarditis following mRNA-based COVID-19 vaccination. E Case series: clinical and cardiac magnetic resonance imaging findings of 4 cases of myocarditis following mRNA-based COVID-19 vaccination. E Case series: symptomatic acute myocarditis in 7 adolescents following mRNA COVID-19 vaccination. E CDC says heart inflammation cases were higher than expected in 16- to 24-year-olds after second Covid vaccine shot, but still rare. E Israel reports link between rare cases of heart inflammation and COVID-19 vaccination in young men. E CDC is investigating several reports that teenagers and young adults may have developed myocarditis after receiving mRNA vaccines. Most cases were mild, more often in males than females, more often following dose 2 than dose 1, and typically, within 4 days after vaccination.
Revisão | Minha abordagem de tratamento da infecção por Clostridioides difficile.
24 Jun, 2021 | 10:56hMy Treatment Approach to Clostridioides difficile Infection – Mayo Clinic Proceedings
[Comunicado de imprensa – Ainda não publicado] Estudo sobre prevenção de trombose em pacientes ambulatoriais de COVID-19 termina precocemente – “Os resultados sugerem que não tratar alguns pacientes sintomáticos, porém estáveis, com terapia anticoagulante ou antiplaquetária pode ser o melhor curso de ação.”
23 Jun, 2021 | 11:01hComentário: Antithrombotics No Help for Stable COVID-19 Outpatients: ACTIV-4b – TCTMD
Infográfico interativo | Interpretação do fluxo lateral do teste de antígeno contra SARS-CoV-2 – “Esta calculadora mostra como a interpretação do resultado do dispositivo de fluxo lateral (lateral flow device – LFD) da Covid-19 pode variar de acordo com a probabilidade pré-teste e a sensibilidade e a especificidade do LFD utilizado.”
23 Jun, 2021 | 11:00hInterpreting a lateral flow SARS-CoV-2 antigen test – The BMJ
Pesquisa laboratorial em pacientes com suspeita de trombocitopenia trombótica (imune) induzida por vacina contra COVID-19.
23 Jun, 2021 | 10:58hPerspectiva | COVID-19: ascensão e ascensão de Delta.
22 Jun, 2021 | 09:13hCOVID-19: The rise and rise of Delta – Sciblogs
Ivermectina é a nova hidroxicloroquina, parte 2 – “Ivermectina não deve ser usada no tratamento da COVID-19 fora do contexto de um estudo clínico.”
22 Jun, 2021 | 09:11hIvermectin is the new hydroxychloroquine, take 2 – Science-Based Medicine
Relacionado: [Preprint] Meta-analysis of RCT: Ivermectin for the treatment of COVID-19 – no effect on all-cause mortality, length of stay, or viral clearance E M-A: Prophylaxis against Covid-19: 1 – no benefit from Hydroxychloroquine; 2 – as studies on ivermectin so far have been small, it remains very uncertain whether ivermectin reduces SARS-CoV-2 infection E Therapeutics and COVID-19 | WHO guideline update advises Ivermectin should only be used to treat COVID-19 within clinical trials E EMA advises against use of ivermectin for the prevention or treatment of COVID-19 outside randomized clinical trials E FDA: Why you should not use Ivermectin to treat or prevent COVID-19 E RCT: Ivermectin does not improve time to resolution of symptoms among adults with mild COVID-19 E NIH Guideline Statement: “there are insufficient data to recommend either for or against the use of ivermectin for the treatment of COVID-19” E Video (5min): Ivermectin for COVID-19 | A Doctor Explains